Policy & Regulation
TrialSpark names new chief medical officer and president and chief financial officer
8 November 2019 -

TrialSpark, a tech-enabled drug development partner involved in improving the speed, quality and innovation of clinical trials, announced yesterday that it has named and Dr Ken Somberg as its new chief medical officer and Quentin Chu as its new president and chief financial officer.

After spending 12 years at Novartis where he served as the therapeutic area head for Clinical Research, and later in Regulatory Affairs for the Transplantation and Immunology Business Unit, Somberg joined Covance Inc as CMO in 2009. Most recently, Somberg served as CMO of Nevakar Inc, focusing on developing innovative products in injectable and ophthalmic therapeutics.

Prior to joining TrialSpark, Chu was CFO at CityMD, with experience in healthcare and private equity having served at Crestview Partners and The Carlyle Group.



Related Headlines